PTHS (Pelthos Therapeutics Inc.) stock: $22.65, $86.7M market cap, $24.2M cash, $62.5M EV, $119.9M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Pipeline assets
ZELSUVMI
Approved · Active Modality: topical gel (nitric oxide-based, NITRICIL platform)
Aliases berdazimer
Partnerships Ligand: owns legacy Novan IP portfolio (assigned March 2025); Company retains ZELSUVMI. Reedy Creek: royalty/milestone purchase agreement — Company obligated to pay Reedy Creek on ZELSUVMI net sales in the U.S., Mexico and Canada
Indications- Molluscum contagiosum (Approved)
Status note ZELSUVMI (berdazimer topical gel, 10.3%) developed using the proprietary NITRICIL nitric oxide-based technology platform; FDA approved. Final Phase 3 enrolled 891 patients.
XEPI
Phase 3 · Active Modality: topical (non-fluorinated quinolone)
Aliases ozenoxacin
Partnerships Ferrer Internacional S.A.: exclusive license to manufacture/commercialize Xepi in the U.S., Puerto Rico and U.S. Virgin Islands (Nov 2025)
Indications- Impetigo (Stage not disclosed)
Status note Two Phase 3 pivotal studies completed in adult and pediatric populations (2 months and older). Acquired from Biofrontera (Nov 2025 asset purchase); exclusive U.S./Puerto Rico/U.S. Virgin Islands commercial license from Ferrer (Nov 2025); preparing for commercial launch.
SB207
Stage not disclosed · Active Modality: topical (NITRICIL platform)
Partnerships Ligand: owns related portfolio rights; Company retains existing rights to SB207
Indications- External genital warts (Stage not disclosed)
Status note Prior clinical work performed; any further development would require the Company to manufacture API.
CC8464
Phase 1 · Active Modality: oral small molecule (peripherally restricted)
Target NaV1.7
Indications- Neuropathic pain (erythromelalgia, idiopathic small fiber neuropathy) (Phase 1)
Status note Designed to not penetrate the CNS, targeting peripheral NaV1.7 channels. Phase 1 studies completed; no immediate plans for toxicology, CMC work or a human proof-of-concept trial.
XEGLYZE (abametapir)
Approved · Active Modality: topical pediculicide (small molecule)
Target metalloproteinase
Partnerships Acquired from Hatchtech Pty Ltd. (Dec 2025)
Indications- Head lice infestation (patients 6 months of age and older) (Approved)
Status note FDA approved July 2020; acquired December 2025 as a complementary commercial product.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.